These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 17960061)

  • 1. Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.
    Jacobi J; Tsao PS
    Am J Nephrol; 2008; 28(2):224-37. PubMed ID: 17960061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Schäffer J; Barbey M; Koch KM; Frölich JC
    J Am Soc Nephrol; 1999 Mar; 10(3):594-600. PubMed ID: 10073610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study.
    Fliser D; Kronenberg F; Kielstein JT; Morath C; Bode-Böger SM; Haller H; Ritz E
    J Am Soc Nephrol; 2005 Aug; 16(8):2456-61. PubMed ID: 15930091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients.
    Ebinç FA; Erten Y; Ebinç H; Paşaoğlu H; Demirtaş C; Taçoy G; Mutluay R; Koç E; Derici U; Reis KA; Bali M; Arinsoy T; Sindel S
    Ren Fail; 2008; 30(4):401-6. PubMed ID: 18569913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease.
    Kielstein JT; Böger RH; Bode-Böger SM; Frölich JC; Haller H; Ritz E; Fliser D
    J Am Soc Nephrol; 2002 Jan; 13(1):170-176. PubMed ID: 11752034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
    Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
    Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.
    Zoccali C; Bode-Böger S; Mallamaci F; Benedetto F; Tripepi G; Malatino L; Cataliotti A; Bellanuova I; Fermo I; Frölich J; Böger R
    Lancet; 2001 Dec 22-29; 358(9299):2113-7. PubMed ID: 11784625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
    Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
    Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
    Kielstein JT; Zoccali C
    Am J Kidney Dis; 2005 Aug; 46(2):186-202. PubMed ID: 16112037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dialysance of asymmetric dimethylarginine (ADMA)--in vivo and in vitro evidence of significant protein binding.
    Kielstein JT; Böger RH; Bode-Böger SM; Martens-Lobenhoffer J; Lonnemann G; Frölich JC; Haller H; Fliser D
    Clin Nephrol; 2004 Oct; 62(4):295-300. PubMed ID: 15524060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients.
    Thaha M; Widodo ; Pranawa W; Yogiantoro M; Tomino Y
    Clin Nephrol; 2008 Jan; 69(1):24-32. PubMed ID: 18226399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of renal replacement therapy on plasma, asymmetric dimethylarginine, nitric oxide and C-reactive protein levels.
    Uzun H; Konukoglu D; Besler M; Erdenen F; Sezgin C; Muderrisoglu C
    Clin Invest Med; 2008; 31(1):E1-7. PubMed ID: 18312743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients.
    Fleck C; Janz A; Schweitzer F; Karge E; Schwertfeger M; Stein G
    Kidney Int Suppl; 2001 Feb; 78():S14-8. PubMed ID: 11168976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases.
    Fleck C; Schweitzer F; Karge E; Busch M; Stein G
    Clin Chim Acta; 2003 Oct; 336(1-2):1-12. PubMed ID: 14500028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between serum asymmetric dimethylarginine and blood pressure in patients with chronic renal failure].
    Zhang WR; Tao LJ; Chen BM
    Hunan Yi Ke Da Xue Xue Bao; 2002 Apr; 27(2):133-4. PubMed ID: 12575339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease.
    Kielstein JT; Bode-Böger SM; Frölich JC; Haller H; Böger RH
    Kidney Int Suppl; 2001 Feb; 78():S9-13. PubMed ID: 11168975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients.
    Kumagai H; Sakurai M; Takita T; Maruyama Y; Uno S; Ikegaya N; Kato A; Hishida A
    Am J Kidney Dis; 2006 Nov; 48(5):797-805. PubMed ID: 17059999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between asymmetric dimethylarginine plasma level and left ventricular mass in hemodialysis patients.
    El Shahawy Y; Soliman Y; Rifaie A; Shenawy H; Behairy M; Mady G
    Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):26-33. PubMed ID: 25579712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease.
    van Guldener C; Nanayakkara PW; Stehouwer CD
    Clin Chem Lab Med; 2007; 45(12):1683-7. PubMed ID: 17937610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.